Swiss Health Policy & Workforce: Swiss business leaders and unions are mobilising ahead of Sunday’s vote on the SVP’s “No to a Switzerland with 10 million!” population cap, warning it could worsen labour shortages across sectors that rely on EU workers, including healthcare and construction. Geneva Health Diplomacy: Switzerland signed a declaration supporting the Gaza Strip, citing a near-collapse of public healthcare and rising skin infections amid restricted basic services. Clinical Research (Switzerland-linked): Oculis (Zug) says the first patient has been randomized in its genotype-based dry eye disease trial PREDICT-1 for licaminlimab targeting a specific TNFR1 group. Alzheimer’s Breakthrough (ETH Zurich): ETH Zurich researchers report an experimental compound (“Compound 10”) that slowed Alzheimer’s progression in mice by targeting a protective biology pathway. Pharma & Trials: Bial discontinued pariceract (BIA 28-6156) after a Phase 2b Parkinson’s study in GBA1 patients missed efficacy endpoints, though safety looked acceptable. Health Tech & Data Privacy: Custodia launched “Sentinel,” a local AI device for sensitive work that keeps data off the internet by processing documents on-device. Health & Society: A Swiss study finds sperm quality is steady, while another report highlights protein-repair defects linked to hidden heart failure.